Macrolide Pharmaceuticals, a Watertown, Mass.-based antibiotics company, completed a $20m financing.
Backers included Advent Life Sciences, Gurnet Point Capital, Novartis Venture Fund, Roche Ventures and SR One.
Founded in 2015 and led by newly joined President and CEO Mahesh Karande, Macrolide develops macrolides for a broad range of multi-drug resistant bacterial infections.
The new funding will accelerate development of the company’s novel, IV and orally available macrolide antibiotics to address serious infections, including work to support filing an Investigational New Drug (IND) application for its lead program that addresses a significant unmet clinical need for antibiotics to treat infections caused by resistant Gram-negative pathogens.
The company is pursuing novel macrolide antibiotics for several illnesses caused by Gram-negative pathogens for which a critical unmet clinical need exists.